NYSE: DHR

Danaher (DHR) Stock Analysis & Forecast

Nov 16 close

$229.91−3.11 (−1.3%)

Gekko Brief

AI summaryNov 16 close

Danaher's week centers on its diagnostics and growth strategy. Cepheid secured IVDR CE marking for its Xpert Respiratory Panel, a multiplex PCR test covering 13 respiratory pathogens that runs on existing GeneXpert systems, expanding the diagnostics portfolio. Separately, CEO Julie Sawyer Montgomery continued detailing a strategy to accelerate core growth beyond the company's mid-single-digit base, citing Cytiva, diagnostics, biologics and AI-enabled drug discovery, including an autonomous lab at Abcam and collaborations with Anthropic and NVIDIA, as the company faces what coverage describes as an execution test.

DHR closed at $229.91, down 1.3% on the day, with the 1-month return at 0.4% and the 6-month return at 40.3%. The close sits above both the 50-day average of $222.96 and the 200-day average of $201.05, with the stock trading within its 52-week range of $160.93 to $242.80. The GekkoIndex reads 56, placing DHR in the Neutral zone, and the price sits 3.3% above Gekko Fair Value of $222.47.

The next earnings date is 27 January 2027, 71 days out and beyond a typical 20-trading-day hold; the prior report on 21 October 2026 beat estimates ($2.11 versus $1.92) with a 2.5% reaction. Over the last 90 days, Congress recorded 1 buy and 0 sells, and 13 covering analysts carry a consensus target of $259.90. Seasonally, the next 20 trading days have averaged 3.7% over 5 years, rising in 4 of them.

Written by AI from the Nov 16, 2026 close and checked automatically against the figures on this page.

Danaher price vs fair value

$229.91$221.37Nov ’25May ’26Nov ’26
Close $229.91200-day averageGekko Fair Value $221.37

Danaher quick facts

Market cap
$161.9B
P/E ratio
38.6
Forward P/E
24.9
EPS, TTM
$6.04
Revenue, TTM
$25.61B
Profit margin
16.9%
Dividend yield
0.65%
Beta
0.80
Volume
3.23M avg 4.07M
1-year return
+3.9%
Typical daily move
±2.8%
Typical 20-day move
±4.7%
50-day average
$222.96
200-day average
$201.05
Next earnings
Jan 27 before open
Shares outstanding
703.5M
52-week range
$160.93$242.80

Danaher swing-trade checklist

Danaher scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive2 mixed0 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $229.91 is above the 50-day ($222.96) and 200-day ($201.05) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    56, Neutral

    Reading 56 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuemixed

    3.9% above

    Price is within 5% of Gekko Fair Value (3.9% above).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 90 days: Congress 1 buy / 0 sales.

    See smart money
  • Earnings risksupportive

    Reports in 71 days

    Next report Jan 27, 2027, 71 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +3.3% on average

    From this point in the calendar, the next 20 trading days averaged +3.3% over 5 years, rising in 5 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Danaher stock chart and price history

Danaher closed at $229.91 on Nov 16, 2026, +3.9% over the past year, inside a 52-week range of $160.93 to $242.80.

Close50-day average200-day averageVolume
Danaher share price, past year, with 50-day and 200-day moving averages and volume$160$180$200$220$240DecJan 2026FebMarAprMayJunJulAugSepOctNov229.91

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+0.4%
3 months
+15.2%
6 months
+40.3%
1 year
+3.9%
The full DHR chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open DHR in Gekko

Follow Danaher through every session

Put DHR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track DHR in GekkoFree for 7 days. No credit card required.

About Danaher

Danaher makes and distributes scientific, medical, industrial and commercial products and services on a global scale, working across science and technology fields rather than a single product line. It is best known for grouping this work into instruments, consumables and related services that support research, healthcare diagnosis and resource management.

The company operates through three segments. Life Sciences covers instrumentation such as mass spectrometers, flow cytometry, genomics and lab automation equipment, centrifuges, particle analysis tools and microscopes, along with consumables tied to gene and cell therapy, bioprocessing, and filtration and purification systems; its customers include pharmaceutical and biopharmaceutical firms, food and beverage makers, medical and life sciences companies, universities, medical schools, research institutes and industrial manufacturers. Diagnostics supplies chemistry, immunoassay, microbiology, hematology, molecular, acute care and pathology systems, reagents, consumables, software and support to hospitals, physician offices, reference labs and other care settings. Environmental & Applied Solutions provides instruments, software, consumables and disinfection systems for treating and managing different water types, plus tools for color and appearance management, packaging quality, printing, marking, coding and traceability for consumer, pharmaceutical and industrial goods.

Danaher's shares are listed on the NYSE under the ticker DHR.

Listed
NYSE
Sector
Health technology
Industry
Medical specialties
Website
danaher.com

Danaher GekkoIndex: the smart money zone

Danaher’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 56, in the Neutral zone, up 2.6 points over five sessions.

010056Neutral

Up 2.6 points over five sessions.

Reading for Nov 16, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying48+1.0%+1.6%+2.9%+2.4%
Accumulation226+0.1%+0.1%+0.6%−0.9%
Neutral (current zone)4120.0%−0.1%−0.5%−0.2%
Distribution20−0.7%+1.0%+1.9%+1.0%
Selling1Too few readings yet

Average DHR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the DHR price, zone by zone.Track DHR in Gekko

Is Danaher stock overvalued? Gekko Fair Value

Danaher trades 3.9% above Gekko Fair Value of $221.37, so the shares are about fair value on Gekko’s estimate.

Gekko’s own estimate of what Danaher shares are worth, recalculated every trading day.

$221.37

Gekko Fair Value, Nov 17, 2026

3.9% above fair value · About fair value

At the end of Aug 2026 the price was 1.1% below the estimate.

Gekko Fair ValueShare price, month end
$221$230Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open DHR in Gekko

Danaher insider and Congress trading

No open-market insider purchases were filed for Danaher, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for DHR in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every DHR insider filing, plotted on the chart in Gekko.Open DHR in Gekko

Congress trades last 90 days

1trade disclosed: 1 purchase and 0 sales.

MemberTypeAmountDisclosed
Ro Khanna
House, CA, purchase
Purchase$1,001 - $15,000Nov 9
traded Oct 13

From congressional disclosures, which report amounts as ranges.

Buybacks

Danaher has been buying back its own shares.

Bought back, quarter ended Jun 26, 2026
$885.0M
As a share of market cap
0.55%
Trailing four quarters
$2.90B

From company filings.

Hedge funds and billionaires quarter ended Sep 30

8of the funds Gekko tracks hold DHR.

2added2opened4trimmed3sold out
Which funds are on each side, name by name.Unlock in Gekko

Danaher earnings: next date and track record

Danaher reports on Jan 27, 2027, before the open (71 days away), and beat the EPS estimate in 7 of its last 8 reports.

7 of 8reports beat the EPS estimate
±6.5%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

−10.0%Jan ’25+6.1%Apr ’25+5.2%Jul ’25+4.7%Oct ’25−6.8%Jan ’26−5.9%Apr ’26−10.9%Jul ’26+2.5%Oct ’26

Last earnings call, Oct 21, 2026 AI summary

What they said
Danaher's Q3 2026 earnings call introduced new CEO Julie Sawyer Montgomery, who outlined a strategic vision to accelerate core revenue growth and gain market share in Life Sciences and Diagnostics. Montgomery acknowledged that growth has not consistently reflected the portfolio's full potential and emphasized stronger execution going forward. The company's strategy centers on leveraging its Danaher Business System and cross-business collaboration across discovery, biotechnology, and diagnostics segments.
Guidance
No specific revenue targets or EPS guidance were provided in this excerpt. Management focused on qualitative objectives: accelerating sustainable core revenue growth, more consistent share gains, and improved translation of portfolio strength into differentiated financial performance.
ReportedEPSSurpriseRevenueSurpriseMove
Oct 21, 2026$2.11
est $1.92
+9.9%$6.55B
est $6.56B
−0.1%+2.5%
Jul 21, 2026$1.94
est $1.84
+5.4%$6.27B
est $6.12B
+2.4%−10.9%
Apr 21, 2026$2.06
est $1.94
+6.2%$5.95B
est $5.98B
−0.5%−5.9%
Jan 28, 2026$2.23
est $2.19
+1.8%$6.84B
est $6.81B
+0.4%−6.8%
Oct 21, 2025$1.89
est $1.72
+9.9%$6.05B
est $6.00B
+0.9%+4.7%
Jul 22, 2025$1.80
est $1.64
+9.8%$5.94B
est $5.84B
+1.7%+5.2%
Apr 22, 2025$1.88
est $1.63
+15.3%$5.74B
est $5.57B
+3.0%+6.1%
Jan 29, 2025$2.14
est $2.14
0.0%$6.54B
est $6.45B
+1.4%−10.0%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Danaher stock forecast and analyst price targets

Analysts’ average 12-month price target for Danaher is $259.90, +13.0% from the last close, from 13 firms rating the stock in the last 90 days.

$259.90consensus 12-month target, +13.0% from the last close
Low $210High $275
Buy13
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 13 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Oct 22CitiBuy, maintained$270+17.4%
Oct 22J.P. MorganBuy, reiterated$270+17.4%
Oct 22TD CowenBuy, reiterated$270+17.4%
Oct 22UBSBuy, reiterated$260+13.1%
Oct 22BarclaysBuy, maintained$260+13.1%
−0.5%average 20-day move after past Neutral readings
+3.3%average move over the next 20 trading days in the last 5 years
±2.8%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Danaher seasonality: the next 20 trading days

Over the next 20 trading days from Nov 17, Danaher averaged +3.3% across the last 5 years, rising in 5 of them.

Next 20 trading days, by year

+2.8%2021+0.9%2022+9.0%2023+1.5%2024+1.9%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days+3.2%5 of 5
Next 10 trading days+4.4%5 of 5
Next 15 trading days+3.4%5 of 5
Next 20 trading days+3.3%5 of 5
Next 30 trading days+4.4%4 of 5

For scale, DHR’s typical 20-trading-day move in either direction is about 4.7%.

Danaher market cap and key statistics

Danaher’s market cap is $161.9B, with a P/E ratio of 38.6 and revenue of $25.61B over the last twelve months.

Valuation

Market cap
$161.9B
P/E ratio
38.6
Forward P/E
24.9
EPS, TTM
$6.04
Gekko Fair Value
$221.37

Trading

Volume
3.23M
Avg volume, 20 days
4.07M
52-week high
$242.80
52-week low
$160.93
Shares outstanding
703.5M

Financials

Revenue, TTM
$25.61B
Profit margin
16.9%
Return on equity
8.2%
Quarterly earnings growth, YoY
+37.8%

Risk and income

Beta
0.80
Typical daily move
±2.8%
Typical 20-day move
±4.7%
Dividend yield
0.65%

Danaher stock news this week

Coverage of Danaher this week reads positive: 12 positive, 5 neutral and 1 negative headlines.

News sentiment positive

Danaher peers

Danaher’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
TMOThermo Fisher Scientific−1.1%Neutral13.7% above
ABTAbbott Laboratories−1.9%Neutral11.1% below
ISRGIntuitive Surgical−1.5%Neutral16.1% above
MDTMedtronic−0.9%Neutral13.6% below
SYKStryker−1.1%Neutral0.6% above
BSXBoston Scientific−2.1%Neutral27.0% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Medical specialties

Danaher stock FAQ

What is Danaher’s market cap?

Danaher’s market cap is $161.9B at the Nov 16, 2026 close of $229.91, with 703.5M shares outstanding. The shares trade on a P/E ratio of 38.6.

What is the Danaher stock forecast?

The consensus analyst 12-month price target for Danaher is $259.90, +13.0% from the last close. Of the 13 firms that rated the stock in the last 90 days, 13 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Danaher stock overvalued or undervalued?

On Gekko’s estimate Danaher is about fair value: the Nov 16, 2026 close of $229.91 is 3.9% above Gekko Fair Value of $221.37. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Danaher report earnings next?

Danaher is expected to report on Jan 27, 2027, before the market opens (71 days away). Analysts expect earnings of $2.49 per share on revenue of $7.49B. Danaher beat the earnings estimate in 7 of its last 8 reports, moving 6.5% on average across the report.

What is Danaher’s 52-week high and low?

Danaher’s 52-week high is $242.80 and its 52-week low is $160.93; it closed at $229.91 on Nov 16, 2026, +3.9% over the past year. Over the last five years the shares peaked at $294.01 on Nov 30, 2021.

Is Danaher stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (trend, smart money, earnings risk and seasonality), 2 as mixed (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Danaher the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,476 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.